Russell Investments Group Ltd. Cuts Holdings in AxoGen, Inc. $AXGN

Russell Investments Group Ltd. trimmed its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN) by 6.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 137,963 shares of the medical equipment provider’s stock after selling 10,156 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.30% of AxoGen worth $2,552,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Divisadero Street Capital Management LP increased its holdings in AxoGen by 2.7% during the fourth quarter. Divisadero Street Capital Management LP now owns 26,972 shares of the medical equipment provider’s stock valued at $444,000 after buying an additional 700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in AxoGen by 4.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider’s stock valued at $398,000 after acquiring an additional 926 shares in the last quarter. State of Wyoming acquired a new stake in AxoGen in the fourth quarter valued at approximately $31,000. Rhumbline Advisers boosted its stake in AxoGen by 3.5% in the first quarter. Rhumbline Advisers now owns 60,264 shares of the medical equipment provider’s stock valued at $1,115,000 after acquiring an additional 2,032 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its stake in AxoGen by 9.8% in the fourth quarter. MetLife Investment Management LLC now owns 26,034 shares of the medical equipment provider’s stock valued at $429,000 after acquiring an additional 2,319 shares in the last quarter. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Trading Up 2.7%

NASDAQ:AXGN opened at $16.26 on Monday. AxoGen, Inc. has a 12 month low of $9.22 and a 12 month high of $21.00. The firm has a fifty day simple moving average of $12.38 and a 200-day simple moving average of $14.44. The company has a current ratio of 4.14, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $748.12 million, a P/E ratio of -162.58 and a beta of 1.00.

Analyst Ratings Changes

Several brokerages have weighed in on AXGN. Wall Street Zen upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Canaccord Genuity Group lowered their target price on shares of AxoGen from $26.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $26.00.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.